Aura Biosciences Q4/FY2024 results: net loss $86.9M, cash $151.1M, Phase 3 CoMpass actively enrolling

Aura Biosciences, Inc.

Net loss $86.9M in FY2024 vs $76.4M in FY2023; R&D expenses $73.3M.
Cash $151.1M as of Dec 31, 2024; runway into 2H 2026.
Phase 3 CoMpass trial actively enrolling; >175 patients pre-screened globally since June 2024.
Phase 2 trial in choroidal metastases initiated; initial data expected 2025.
Phase 1 NMIBC data showed clinical complete responses; Tony Gibney appointed Senior Finance and Strategy Advisor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.